Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Luis MezaDavid F McDermottBernard EscudierThomas E HutsonCamillo PortaElena VerzoniMichael B AtkinsVijay KasturiSumanta K PalBrian RiniPublished in: The oncologist (2022)
Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.